-

12:46:14 AM

ZLAB Stock News

ZLAB - Zai Lab Limited

10/11/21 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations in October Investor Conferences

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in

RHEA-AI

neutral

10/05/21 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative

RHEA-AI

very positive

10/04/21 9:10 AM

Nasdaq : ZLAB

Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the

RHEA-AI

very positive

10/04/21 7:30 AM

Nasdaq : NVCR, ZLAB

clinical trial

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Novocure, a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab Limited, an innovative commercial-stage biopharmaceutical company, today announced that the final patient has been enrolled in a Novocure-sponsored phase 2 pilot trial conducted by Zai Lab evaluating the...

RHEA-AI

neutral

10/04/21 7:30 AM

Nasdaq : ZLAB

clinical trial

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company working to

RHEA-AI

neutral

09/22/21 12:22 PM

Nasdaq : ZLAB

Zai Lab Holds Virtual Research and Development Day

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage

RHEA-AI

very positive

09/16/21 7:30 AM

Nasdaq : ZLAB

Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that it will expand its operations in the U.S. and establish a key presence in the Cambridge biotechnology hub.

RHEA-AI

very positive

09/14/21 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage

RHEA-AI

very positive

09/09/21 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab to Host Virtual Research and Development Day on September 22, 2021

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced it will host a Virtual R&D Day for analysts and

RHEA-AI

neutral

08/25/21 8:30 AM

Nasdaq : ZCMD, ZLAB

low float

Zhongchao Inc. Expands Patient Management Business to Ovarian Cancer Market

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 8 9 10 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.